Kiora Pharmaceuticals, Inc.

Aug 19, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Kiora Pharmaceuticals has licensed the rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation in South Korea. This agreement includes a $1 million upfront payment and potential royalties on future sales. KIO-301 is designed to restore light sensitivity in patients with retinitis pigmentosa, a rare inherited retinal disease. CKD will manage development and commercialization efforts in South Korea.

Aug 7, 2026

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Kiora Pharmaceuticals reported its Q2 2026 financial results, highlighting advancements in its clinical trials for retinal diseases. The company is progressing in the Phase 2 ABACUS-2 and KLARITY trials, with strong patient demand noted. Kiora also secured a private placement to bolster its financial position, ensuring operational funding into late 2028.

Jul 2, 2026

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event will feature an investor fireside chat, which will be accessible live and via replay for 90 days. Kiora is advancing therapies for retinal diseases, including KIO-301 for retinitis pigmentosa and KIO-104 for macular edema.

Jun 18, 2026

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Kiora Pharmaceuticals presented preclinical data at the Epilepsy Foundation Pipeline Conference, showing that KIO-300 effectively suppressed seizure activity in a temporal lobe epilepsy model. The results indicate significant reductions in epileptiform activity, suggesting the drug's potential for broader neurological applications. Kiora aims to explore further therapeutic uses of KIO-300 beyond its current focus on vision restoration.

Jun 18, 2026

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in

Kiora Pharmaceuticals has announced positive preclinical results at the Epilepsy Foundation Pipeline Conference regarding its ion channel modulator, KIO-300. The data showed that KIO-300 significantly suppressed seizure activity in a temporal lobe epilepsy model, with effects beginning 42 minutes post-treatment and persisting during follow-up periods. This suggests a promising therapeutic potential for KIO-300 beyond its initial applications in ophthalmology, indicating possible uses in treating epilepsy and other neurological disorders.

May 8, 2026

KPRX1. Phases

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Encinitas, CA

Kiora Pharmaceuticals has reported positive first-quarter financial results for 2026 and updates on its clinical pipeline focusing on treatments for retinal diseases. The company sees strong patient enrollment in the Phase 2 ABACUS-2 study of KIO-301 and has validated its potential through a publication in Nature Medicine. Significant progress is also noted for the KLARITY study regarding KIO-104, with a pre-defined safety review upcoming. Moreover, Kiora has secured additional funding from a strategic equity financing, enhancing its operational runway into late 2028.

Apr 2, 2026

Kiora Pharmaceuticals Announces Management Team Changes Encinitas, California

Kiora Pharmaceuticals announced management changes with the departure of Chief Development Officer Eric J. Daniels, M.D., MBA, effective April 17, 2026. The company expressed gratitude for his contributions while initiating a search for a successor. Kiora remains dedicated to its pipeline aimed at treating retinal diseases, with ongoing clinical trials KIO-301 and KIO-104 showing positive advancements in patient enrollment. The company continues to receive approvals for clinical trial progression, indicating a forward momentum in development.

Mar 25, 2026

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and

Kiora Pharmaceuticals announced the closure of a private placement providing up to $24 million in gross proceeds, with $5 million received upfront and the remaining contingent on milestone-based warrants. The company intends to utilize these funds for general corporate purposes, including strategic business development and research efforts. The private placement involved the sale of common stock and warrants, with significant investors being Perceptive Advisors and ADAR1 Capital Management. This financial boost is expected to facilitate Kiora's ongoing development of therapies for retinal diseases.

Mar 25, 2026

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials Encinitas, California

Kiora Pharmaceuticals has reported its financial results for Q4 and full year 2025, detailing the advancement of its retinal disease treatments. The company has commenced two active Phase 2 clinical trials, with KIO-301 and KIO-104 both in patient dosing stages. Despite ending the year with a solid cash reserve that extends operations into late 2027, Kiora also faced a significant net loss partially due to an impairment charge. The firm is optimistic about its partnerships and pipeline progression, aiming for initial clinical data readouts in 2027.

Nov 7, 2025

Kiora Pharmaceuticals Reports Third Quarter 2025 Results Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases Encinitas, California

Kiora Pharmaceuticals (NASDAQ: KPRX) has reported its third-quarter 2025 financial results, highlighting advancements in its clinical pipeline for retinal diseases. The company is currently conducting two actively enrolling Phase 2 clinical trials, KLARITY and ABACUS-2, aimed at treating retinal inflammation and retinitis pigmentosa. Kiora ended the quarter with $19.4 million in cash and reported a small net income, a significant improvement from the previous year's losses. The firm's ongoing financial management and collaborations are set to support its development efforts through to late 2027.

Aug 8, 2025

Kiora Pharmaceuticals Reports Second Quarter 2025 Results Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Encinitas, California

Kiora Pharmaceuticals has reported its financial results for Q2 2025, highlighting advancements in its therapeutic pipeline for retinal diseases. The company has initiated two Phase 2 clinical trials, KLARITY and ABACUS-2, targeting retinal inflammation and vision restoration, respectively. Kiora also strengthened the market exclusivity of KIO-104 and entered a partnership with Senju Pharmaceutical that could yield substantial financial benefits. Despite these advancements, Kiora continues to incur losses, reporting a net loss consistent with prior periods.

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia - Total potential deal value of $110 million plus royalties - Kiora to receive an immediate $1.25 million ex

Kiora Pharmaceuticals announced a partnership with Senju Pharmaceutical, granting Senju an exclusive option for the development and commercialization of KIO-301 for retinal diseases across key Asian markets. The agreement has a total potential value of $110 million, including an immediate $1.25 million option fee. KIO-301 is currently in Phase 2 trials and aims to offer therapeutic options for inherited retinal diseases, particularly retinitis pigmentosa. This deal is expected to enhance Kiora's financial stability and extend the commercial reach of KIO-301.

May 9, 2025

Kiora Pharmaceuticals Reports First Quarter Results Initiating Two Phase 2 Trials for Treatment of Retinal Diseases Cash and Short-term Investments Expected to Fund Operations into Late 2027 Encinitas, California

Kiora Pharmaceuticals has reported its first quarter results for 2025, announcing the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301, targeting retinal diseases. The company's cash and short-term investments are expected to fund operations until late 2027, providing a robust financial runway. While Kiora experienced a net loss this quarter, the approval for new trials and positive preclinical data strengthen its position in the field of retinal therapeutics. Ongoing patient enrollment and collaborations may further enhance the company's prospects.

Kiora Pharmaceuticals Reports 2024 Results Retinal Disease Drug Development Pipeline Continues to Advance Cash and Short-term Investments Expected to Fund Operations into 2027 Encinitas, California

Kiora Pharmaceuticals has announced positive developments in its retinal disease drug pipeline, including the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301. The company ended 2024 with $26.8 million in cash, which is projected to fund operations until 2027. These trials aim to address important retinal disorders, with initial data expected in 2026. Despite a reported net loss in Q4 2024, the company is strategically positioned to advance its therapeutic candidates.

Nov 8, 2024

Kiora Pharmaceuticals Reports Third Quarter Results Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California

Kiora Pharmaceuticals reported its financial results for Q3 2024, highlighting advancements in its retinal disease pipeline, including two Phase 2 studies. The company has received approval to begin the ABACUS-2 trial for KIO-301 and is finalizing plans for the KLARITY trial for KIO-104, which targets multiple retinal inflammatory diseases. Kiora ended the quarter with $29 million in cash, indicating a strong financial position to support ongoing developments. The company anticipates increased research and development expenses as it begins patient enrollment for these studies.

Oct 29, 2024

Document Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California

Kiora Pharmaceuticals has announced the receipt of Investigational New Drug approval to start the ABACUS-2 Phase 2 clinical trial for KIO-301, a treatment aimed at restoring vision in patients with retinitis pigmentosa. This trial will investigate the safety and efficacy of KIO-301 in a multi-center setup across Australia and enroll 36 patients. Notably, KIO-301 is a small molecule that activates in the presence of light, providing potential vision restoration regardless of individual gene mutations. The trial aims to validate breakthrough functional vision endpoints essential for subsequent registration studies in major regions including the US and Europe.

Aug 9, 2024

Kiora Pharmaceuticals Reports Second Quarter Results Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Encinitas, California

Kiora Pharmaceuticals has reported its second-quarter results as it advances its pipeline targeting retinal diseases. The company is set to initiate two Phase 2 clinical trials for its innovative small molecules, KIO-301 and KIO-104. Kiora maintains a solid cash position, aiming for a runway through 2027, facilitating these developments. Notably, Kiora received Orphan Medicinal Product Designation from the EMA, which could bolster its position in the market. However, the company still faces financial challenges, including a net loss in the recent quarter.

Jul 30, 2024

KPRXFDA Updates

Document Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies Encinitas, CA

Kiora Pharmaceuticals has gained Orphan Medicinal Product Designation for KIO-301 from the European Medicines Agency, aimed at treating inherited retinal dystrophies. This designation grants Kiora significant market exclusivity and regulatory benefits in Europe, following similar status in the U.S. The company plans to advance clinical development with a Phase 2 trial set to begin soon. KIO-301 is designed as a new therapeutic approach to address vision loss due to genetic retinal disorders.

Jul 1, 2024

Document Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors Ken Gayron to Step Down as a Member of the Company's Board

Kiora Pharmaceuticals has appointed Lisa Walters-Hoffert to its Board of Directors while Ken Gayron steps down due to other commitments. Walters-Hoffert, a seasoned biotech executive, will chair the audit committee and contribute her extensive experience in strategic development and finance to aid Kiora's growth. The company is actively working on advancing its investigational treatments, including KIO-301, and has secured funding to support its research efforts for at least two years. The change in leadership aims to strengthen Kiora's direction in developing novel therapies for retinal diseases.

May 10, 2024

Kiora Pharmaceuticals Reports First Quarter Results Update on Pipeline of Drugs Targeting Retinal Disease Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Th a Open Innovation, exp

Kiora Pharmaceuticals has announced its first quarter financial results and updates on its retinal disease drug pipeline. Notably, the company plans to initiate a Phase 2 trial for KIO-301 for retinitis pigmentosa in Q4 2024 and a Phase 2 trial for KIO-104 in 2025. Kiora ended the quarter with $31.3 million in cash, benefiting from a strategic partnership with Th a Open Innovation. The collaboration is poised to significantly support the development of both KIO-301 and KIO-104, with potential implications for treating various retinal conditions.

Mar 25, 2024

Kiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California

Kiora Pharmaceuticals reported its 2023 financial results and announced plans to initiate Phase 2 trials for its retinal disease treatments, KIO-301 and KIO-104, in 2024. The company secured a strategic partnership with TOI, gaining a $16 million upfront payment, which is expected to support operations through 2026. Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa. Kiora also plans to pursue additional studies and orphan drug designations for its product candidates.

expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Contact Information Investors kiorapharma.com

Kiora Pharmaceuticals has announced a successful private placement aimed at raising up to approximately $45 million. This includes an upfront financing of $15 million with the potential for an additional $30 million through warrant exercises. The funding will support the development of KIO-104 for posterior non-infectious uveitis and other inflammatory conditions. Notable healthcare investment firms are participating, indicating confidence in Kiora's pipeline and operations.

Jan 31, 2024

▼ -6.2%on this news· ran to +44% by day 1shared move

Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases Total Deal Value of up to $301 Million includes $16 Million Up

Kiora Pharmaceuticals has entered a strategic partnership with Th a Open Innovation to develop and commercialize KIO-301 for inherited retinal diseases. The agreement involves a total deal value of $301 million, including an upfront payment of $16 million and potential future milestones. Kiora plans to initiate a Phase 2 clinical trial for retinitis pigmentosa in early 2024, following successful Phase I II data. The partnership aims to leverage TOI's resources for broader development and commercialization efforts while focusing initially on significant vision improvement in affected patients.

Nov 9, 2023

Kiora Pharmaceuticals Reports Q3 2023 Results Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa Encinitas, California

Kiora Pharmaceuticals reported promising Q3 2023 results, highlighting the safe and effective profile of KIO-301 based on the ABACUS-1 study in retinitis pigmentosa. The company plans to further develop KIO-301 for other inherited retinal diseases through new Phase 2 trials. A meeting with the FDA is planned for Q4 2023 to discuss future clinical study designs and endpoints. Despite positive advancements, the company reported an increase in net loss year-over-year.

Sep 21, 2023

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Kiora Pharmaceuticals has appointed Praveen Tyle, PhD, as its new Chairman, succeeding Paul Chaney who is retiring after 17 years. Tyle, who is already a director at the company, is expected to lead with valuable experience in guiding Kiora's development of new treatments for eye disease, particularly focusing on KIO-301's advancement. The CEO expressed gratitude to Chaney for his long-term contributions and highlighted the strategic direction under Tyle's leadership.

Sep 1, 2023

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 Encinitas, CA

Kiora Pharmaceuticals announced that its Special Meeting of Stockholders, initially held on August 31, 2023, was adjourned to September 27 due to insufficient quorum. The company is seeking additional votes to meet the one-third voting power required for quorum. During this period, Kiora is working with a proxy solicitor to encourage stockholders to participate. If the necessary votes are not obtained, the meeting may need to be adjourned again, leading to additional expenses.

Aug 8, 2023

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress - Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concep

Kiora Pharmaceuticals reported positive preliminary data from its Phase 1 clinical trial of KIO-301 for treating Retinitis Pigmentosa during Q2 2023. The data demonstrated safety and tolerability at the lowest dose, prompting plans for higher dose trials. The company aims to focus on rare retinal diseases, expanding KIO-301's application to include Choroideremia and Stargardt's Disease. With a new strategy in place, Kiora is actively seeking partnerships while also pursuing clinical milestones and FDA discussions for its products.

Aug 1, 2023

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Kiora Pharmaceuticals, Inc. has appointed Carmine Stengone to its board of directors. Stengone, current President and CEO of Pipeline Therapeutics, brings valuable experience in developing precision medicines for neurodegenerative diseases. His background in small molecules and degenerative diseases is expected to guide Kiora's strategy and clinical development. The company continues to advance its promising pipeline, particularly focusing on KIO-301, which may restore vision for patients with retinitis pigmentosa.

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx Sentrx gains access to Kiora's

Kiora Pharmaceuticals and Sentrx Animal Care have amended their licensing agreement for the KIO-201 product candidate. The amendment allows Kiora to avoid up to $4.75M in near-term milestone payments while granting Sentrx access to Kiora's patents related to the use of hyaluronic acid technology with antibiotics in animal health. Kiora will continue to receive a royalty on net sales of products covered by these patents, enhancing its financial position and flexibility. The changes are expected to benefit both companies and support their respective innovations in veterinary care.

Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering Encinitas, California--(Newsfile Corp.

Kiora Pharmaceuticals has announced the pricing of an underwritten public offering aimed at raising approximately $5.5 million. The offering includes common stock, convertible preferred stock, and multiple types of warrants. The expected closing date for this offering is June 6, 2023, pending customary closing conditions. This move is seen as a step to facilitate the company's ongoing development efforts for its ophthalmic disease treatments.

May 9, 2023

Kiora Pharmaceuticals Reports First Quarter Results Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments Encinitas, CA

Kiora Pharmaceuticals reported significant advancements in their ocular drug pipeline during the first quarter of 2023. The company highlighted positive results from studies on KIO-301, which aims to improve light perception in patients with Retinitis Pigmentosa, and KIO-201, targeting chronic ocular wounds. Additionally, Kiora initiated a Phase 2 trial for KIO-101, focusing on ocular surface disease related to autoimmune conditions. The firm is positioned to continue enrollment in ongoing studies and plans to report more results within the year.

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind Encinitas, California

Kiora Pharmaceuticals presented encouraging preliminary results from its clinical trial of KIO-301, an investigational treatment for retinitis pigmentosa. The treatment demonstrated the capability to restore light perception in patients with severe visual impairment. Initial data showed improvements in functional vision and neural activity in the visual cortex, suggesting significant potential for KIO-301 as a therapy for this condition. The trial aims to further evaluate the safety and efficacy of the drug, with plans for dose escalation and comprehensive reporting of results later this year.

Kiora Pharmaceuticals Reports 2022 Financial Results Provides Update on Clinical Development Progress

Kiora Pharmaceuticals has reported its 2022 financial results, highlighting progress in its clinical development of innovative treatments for rare eye diseases. The company is advancing three key product candidates, including the promising KIO-301 for Retinitis Pigmentosa, with early results indicating potential vision restoration. Kiora also plans to present additional data at the upcoming ARVO meeting. Despite achieving operational efficiencies, the company recorded a net loss of $13.6 million, which raises concerns about its financial health moving forward.

Feb 7, 2023

▲ +38.7%on this news· ran to +112% by day 1

Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases Encinitas, California

Kiora Pharmaceuticals has received approval for a Phase 2 study of KIO-101, intended for the treatment of ocular manifestations in autoimmune diseases, particularly rheumatoid arthritis. This multi-center trial will involve 120 patients and aims to assess the safety and efficacy of KIO-101 eye drops, which address significant ocular symptoms that current treatments do not effectively manage. The company believes this drug could serve as a viable option for patients suffering from ocular surface disease, potentially impacting approximately 3.43 million people in the U.S.

Jan 9, 2023

Kiora Pharmaceuticals, Inc. NASDAQ: KPRX January 2023 | Corporate Outlook 2 Forward Looking Statements Some of the statements in this presentation are "forward - looking" and are made pursuant to the safe harbor provisio

Kiora Pharmaceuticals, Inc. has provided an overview of its corporate outlook and ongoing clinical development efforts. The company is advancing several product candidates, including KIO-101, KIO-201, and KIO-301, which target rare ophthalmic diseases. KIO-301 has received orphan drug designation, while a Phase 2 trial of KIO-101 is set to initiate in 2023. Despite positive developments, the company acknowledges various risks and uncertainties that could impact the commercial success of their products.

Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants Salt Lake City, Utah--(Newsfile Corp.

Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants Salt Lake City, Utah--(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it ha

Oct 13, 2022

Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Salt Lake City, Utah--(

Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Salt Lake City, Utah--(October 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that it has received a Bid Price Compliance Letter from The Nasdaq Stock

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split Salt Lake City, Utah -- (

Pharmaceuticals to Implement 1-for-40 Reverse Split Salt Lake City, Utah -- (September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following th

Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Salt Lake City, Utah--(Newsfile Corp.

Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of F

Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering Salt Lake City, Utah--(Newsfile Corp.

Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering Lake City, Utah--(Newsfile Corp. - July 22, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gr

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Salt Lake City, Utah

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Salt Lake City, Utah -- May 31, 2022 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the

Feb 1, 2022

Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board SALT LAKE CITY, UT, Feb 1, 2022 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independe

Jan 11, 2022

CORPORATE OVERVIEW January 2022 2 Forward Looking Statements Some of the statements in this press release are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Re

CORPORATE OVERVIEW January 2022 2 Forward Looking Statements Some of the statements in this press release are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements inc

Dec 15, 2021

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors SALT LAKE CITY, UT, Dec 15, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. H

Dec 14, 2021

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease SALT LAKE CITY, UT, Dec 14, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its ve

Nov 15, 2021

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities. “We recen

Nov 8, 2021

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy

EyeGate is Now Kiora Pharmaceuticals; Provides Sharpened Clinical Development Strategy SALT LAKE CITY, UT, November 8, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will tra

Oct 26, 2021

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to

EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. Bayon Therapeutics' portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 - EyeGate Pha

Sep 14, 2021

EyeGate Pharmaceuticals (NASDAQ: EYEG) Sept 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform

EyeGate Pharmaceuticals (NASDAQ: EYEG) Sept 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements include

Aug 10, 2021

EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules WALTHAM, MA

Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq MA, August 10, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and

Jul 26, 2021

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceuti

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small mo

May 27, 2021

Treating inflammatory and immune diseases May 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Refor

Treating inflammatory and immune diseases May 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements includ

Apr 1, 2021

EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors WALTHAM, MA

EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors WALTHAM, MA, April 01, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing products for treating inflammato

Feb 1, 2021

Lead Independent Director Charter If the Chairman of the Board of EyeGate Pharmaceutical, Inc. (the "Company") is also an employee of the Company or its subsidiaries, then the independent members of the Board of Director

Lead Independent Director Charter If the Chairman of the Board of EyeGate Pharmaceutical, Inc. (the "Company") is also an employee of the Company or its subsidiaries, then the independent members of the Board of Directors will annually elect with a majority vote an independent

Jan 6, 2021

EyeGate Enters Into Agreement for $8.0 Million Private Placement WALTHAM, MA

EyeGate Enters Into Agreement for $8.0 Million Private Placement WALTHAM, MA, January 06, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune d

Dec 21, 2020

EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Me

EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Ta

Sep 14, 2020

NASDAQ: EYEG Corporate Presentation September 2020 TB D 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements rel

NASDAQ: EYEG Corporate Presentation September 2020 TB D 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437

Jun 1, 2020

NASDAQ: EYEG Corporate Presentation 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospec

NASDAQ: EYEG Corporate Presentation 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437 product candidates ,

Mar 31, 2020

EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study WALTHAM, MA

Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study MA, March 31, 2020 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announ

Dec 31, 2019

EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules WALTHAM, MA

Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MA, December 31, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorde

Dec 17, 2019

EyeGate Pharma Receives $1.9 Million From Exercised Warrants WALTHAM, MA

Pharma Receives $1.9 Million From Exercised Warrants WALTHAM, MA, December 17, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the exercise of warrants subsequent

Dec 2, 2019

EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study WALTHAM, MA

Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study WALTHAM, MA, December 2, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the

Nov 22, 2019

EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study WALTHAM, MA

Pharma Hits Primary Endpoint in PRK Pivotal Study WALTHAM, MA, November 22, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today

Sep 30, 2019

EyeGate Enters Into Agreement for $1.9 Million Private Placement WALTHAM, MA

EyeGate Enters Into Agreement for $1.9 Million Private Placement WALTHAM, MA, September 30, 2019 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today anno

Sep 23, 2019

EyeGate Pharma Regains Nasdaq Listing Compliance

Pharma Regains Nasdaq Listing Compliance WALTHAM, Mass., Sept. 23, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the

Aug 30, 2019

NASDAQ: EYEG Corporate Presentation Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects

NASDAQ: EYEG Corporate Presentation Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437 product candidates , f

Aug 29, 2019

EYEGATE PHARMA ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE AUGUST 30, 2019 WALTHAM, MA

PHARMA ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE AUGUST 30, 2019 WALTHAM, MA, August 29, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, anno

May 14, 2019

EyeGate Pharma Receives Positive Nasdaq Listing Determination

Pharma Receives Positive Nasdaq Listing Determination WALTHAM, Mass., May 14, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the co

Dec 12, 2018

NASDAQ: EYEG Corporate Presentation Two Versatile Platforms Moving Towards Commercialization December 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant

NASDAQ: EYEG Corporate Presentation Two Versatile Platforms Moving Towards Commercialization December 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to t

Nov 13, 2018

EYEGATE PHARMA ANNOUNCES POSITIVE RESULTS IN SECOND PRK STUDY Data confirms results from earlier study

ANNOUNCES POSITIVE RESULTS IN SECOND PRK STUDY results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate's Ocular Bandage Gel (OBG)

Oct 2, 2018

EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care

EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform techn

Sep 25, 2018

EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules

EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules WALTHAM, Mass., Sept. 25, 2018 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating dis

Sep 5, 2018

NASDAQ: EYEG Investor Presentation Two Versatile Platforms Moving Towards Commercialization September 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant

NASDAQ: EYEG Investor Presentation Two Versatile Platforms Moving Towards Commercialization September 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to t

Sep 4, 2018

EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis WALTHAM, MA., September 04 , 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with

Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis WALTHAM, MA., September 04, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and d

May 16, 2018

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd WALTHAM, Mass., May 16, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating

Apr 17, 2018

EyeGate Announces Completion of $11.25 Million Public Offering

EyeGate Announces Completion of $11.25 Million Public Offering WALTHAM, Mass., April 17, 2018 - EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating d

Apr 13, 2018

EyeGate Announces $11.25 Million Public Offering

Announces $11.25 Million Public Offering Mass., April 13, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the

Mar 12, 2018

NASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Follow us on Facebook, LinkedIn and Twitter Fo

Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's lead product EGP - 437, for the timing and outcom

Feb 26, 2018

www.eyegatepharma.com NASDAQ: EYEG NASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com OBG: The Ocular Liquid Bandage A crosslinked hyaluronic acid (CMHA -

www.eyegatepharma.com NASDAQ: EYEG Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's lead product E

Feb 5, 2018

EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints

Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints Mass., February 05, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specia

Jan 8, 2018

CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Forward Looking Statements Some of t

CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Forward Looking Statements Some of the matters discussed in this presentation contain forward -

Jan 4, 2018

EyeGate Promotes Sarah Romano to Chief Financial Officer Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase

EyeGate Promotes Sarah Romano to Chief Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., January 04, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage

Nov 9, 2017

Two Versatile Platforms Moving Towards Commercialization Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements rel

Two Versatile Platforms Moving Towards Commercialization Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's EGP - 437 and OBG

Sep 12, 2017

Providing innovative products that enhance drug efficacy and patient compliance to improve vision CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma

Providing innovative products that enhance drug efficacy and patient compliance to improve vision CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Forward Looking Statements Some of the matters discuss

Sep 11, 2017

EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships WALTHAM, Mass., Sept ember 11, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty

Launches Social Media Pages to Enhance Investor and Trade Relationships Mass., September 11, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products u

Jun 14, 2017

EyeGate Announces Completion of $10.0 Million Public Offering

Announces Completion of $10.0 Million Public Offering Mass., June 14, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders

Jun 9, 2017

EyeGate Announces $10.0 Million Public Offering

Announces $10.0 Million Public Offering WALTHAM, Mass., June 9, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of

May 4, 2017

EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel

Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel Mass., May 4, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company that focuses on developing and co

Feb 23, 2017

EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this pr

EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involv

Feb 21, 2017

International Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Valeant EyeGate Pharmaceuticals Elif McDonald Lee Roth / Janhavi Mohite 514-856-3855

St. Elz ar Blvd. West Contact Information: Valeant EyeGate Pharmaceuticals Elif McDonald Lee Roth / Janhavi Mohite 514-856-3855 646-536-7012 / 7026 877-281-6642 (toll free) lroth@theruthgroup.com / jmohite@theruthgroup.com elif.mcdonald@valeant.com Chris Kittredge/Jared Levy

Feb 6, 2017

EyeGate Pharmaceuticals Announces Executive Promotions Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations,

EyeGate Pharmaceuticals Announces Executive Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations, respectively WALTHAM, Mass., February 06, 2017 - EyeGate Pharmaceu

Jan 30, 2017

EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 40 82 140 147 189 107 177 194 217 109 141 72 254 215 84 176 216 190 142 163 194 241 249 244 191 201 221 25 52 87 1 Forward Looki

Nov 17, 2016

KPRXFDA Updates

FDA Confirms a 510(k) De Novo Path for EyeGate's Device, the Ocular Bandage Gel, Following Pre-Submission Meeting Top-Line Data from First-in-Human Pilot Study Expected by Year-End 2016

Confirms a 510(k) De Novo Path for EyeGate's Device, the Ocular Bandage Gel, Following Pre-Submission Meeting Data from First-in-Human Pilot Study Expected by Year-End 2016 Mass., November 17, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a

Sep 12, 2016

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this pr

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involv

Aug 1, 2016

EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients

Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients Mass., August 1, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmac

Jun 30, 2016

EyeGate Announces Completion of $3.77 Million Registered Direct Offering

Announces Completion of $3.77 Million Registered Direct Offering Mass., June 30, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery sy

Jun 27, 2016

EyeGate Announces $3.77 Million Registered Direct Offering

Announces $3.77 Million Registered Direct Offering Mass., June 27, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for trea

Jun 1, 2016

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation Forward Looking Statements Some of the matters discussed in this pres

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation Forward Looking Statements Some of the matters discussed in this presentation contain forward-looking statements that involve

May 24, 2016

EyeGate Pharma Announces At The Market Issuance Program Waltham, Mass.

EyeGate Pharma Announces At The Market Waltham, Mass., May 24, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (the "Company") announced today that it has entered into an At The Market Issuance ("ATM") Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (t

Mar 7, 2016

EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Acquisition of Jade Therapeutics 1 Forward Looking Statements Some of the matters discussed

EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Acquisition of Jade Therapeutics 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements t

Jan 19, 2016

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation January 2016 1 Forward Looking Statements Some of the matters discuss

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation January 2016 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statement

Sep 8, 2015

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Rodman & Renshaw Annual Global Investment Conference 09 September 2015 1 Forward Looking Sta

Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Rodman & Renshaw Annual Global Investment Conference 09 September 2015 1 Forward Looking Statements Some of the matters discussed in this presentation

Aug 14, 2015

C O M P A N Y I N T E R V I E W EyeGate Pharmaceuticals, Inc. (EYEG) STEPHEN FROM has served as the President, Chief Executive Officer and Director of EyeGate Pharmaceuticals, Inc., since October 2005. Prior to joining E

EyeGate Pharmaceuticals, SECTOR - PHARMACEUTICALS (AZC611) TWST: Could you provide a brief overview of the company and also talk about why it was now that you've decided to go public? From: EyeGate Pharmaceuticals focuses on the ophthalmic area, and what we actually have is a

Jul 30, 2015

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants

EyeGate Pharmaceuticals Announces Pricing of $10,000,000 of Common Stock and Warrants WALTHAM, Mass., July 30, 2015 - Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercia

Jul 10, 2015